Results 71 to 80 of about 15,404 (212)

Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats

, 2016
Nouf M Al-Rasheed,1 Nawal M Al-Rasheed,1,2 Iman H Hasan,1 Maha A Al-Amin,1 Hanaa N Al-Ajmi,1 Ayman M Mahmoud3 1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, 2Department of Pharmaceutical Sciences, College of ...
Al-Rasheed NM, Mahmoud AM, Al-Amin MA, Hasan IH, Al-Ajmi HN   +4 more
core  

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Sitagliptin-induced hemolysis

, 2010
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent.
Weena Stanley, MV Nagaraja, Shivashankara, K. N., Ragini Bekur, Stanley, Weena, KN Shivashankara, Bekur, Ragini, Nagaraja, M. V.   +7 more
core   +1 more source

Pancreatic Safety of Sitagliptin in the TECOS Study. [PDF]

, 2016
Objective We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).
Josse, Robert, Lachin, John M, Peterson, Eric D, Tankova, T, Lachin, John M., Peterson, Eric D., Grado, Carlos R., Holman, RR, Engel, Samuel S, Engel, SS, Stevens, Susanna R, TECOS Study Group, Bethel, M Angelyn, Patel, Keyur, Buse, John B., Wainstein, Julio, Buse, JB, Tankova, Tsvetalina, Buse, John B, Lokhnygina, Yuliya, Bethel, MA, Bethel, M. Angelyn, Green, JB, Stevens, SR, Aschner, P, Patel, K, Engel, Samuel S., Aschner, Pablo, Holman, Rury R., Wainstein, J, Holman, Rury R, Green, Jennifer B., Stevens, Susanna R., Green, Jennifer B, Lachin, JM, Josse, R, Grado, CR, Grado, Carlos Raffo, Lokhnygina, Y, Peterson, ED   +39 more
core   +1 more source

Beat‐to‐beat variability of ventricular repolarization reveals sex‐specific instability and proarrhythmic risk

The Journal of Physiology, EarlyView.
Abstract figure legend A mechanistic framework linking sex‐dependent dynamical instability to proarrhythmic risk. Sex‐specific human ventricular models show that upstream modulators, including biological sex, hormones, drugs and heart disease, promote steeper APD restitution in female than male and enhance dynamical instability.
Daisuke Sato, Lorenzo Santini, Raffaele Coppini, Eleonora Grandi   +3 more
wiley   +1 more source

Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods

Chirality, Volume 38, Issue 7, July 2026.
Chirality is crucial in drug development since both biological targets in the organism and the majority of pharmaceutical compounds are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs. Asymmetric synthesis and racemic resolution are the two most common methods for obtaining enantiopure drugs ...
Burcu Karayavuz, Cigdem Karaaslan Kirmizioglu   +1 more
wiley   +1 more source

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway

, 2017
Esther Civantos,1,2 Enrique Bosch,1 Elisa Ramirez,1 Olha Zhenyukh,1 Jesús Egido,1,2 Oscar Lorenzo,1,2 Sebastián Mas1,2 1Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Autonoma University ...
Ramirez E, Lorenzo O, Bosch E, Mas S, Egido J, Civantos E, Zhenyukh O   +6 more
core  

Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells

Journal for ImmunoTherapy of Cancer
Background Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds
Zheng Huang, Jiaqi Zhang, Qi Peng, Lui Ng, Ian-Ian Ng, Tingzhong Tian, Kaimin Xiao, Xiyue Yao, Jianyang Zeng, Haidong Tang   +9 more
doaj   +1 more source

Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDiminished growth hormone (GH) is associated with impaired endothelial function and fibrinolysis. GH‐releasing hormone is the primary stimulus for GH secretion and a substrate of dipeptidyl peptidase‐4.
Jessica R. Wilson, Nancy J. Brown, Hui Nian, Chang Yu, Martin Bidlingmaier, Jessica K. Devin   +5 more
doaj   +1 more source

Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study (REVISE Study)

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee, Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jong Chul Won   +14 more
wiley   +1 more source